| __timestamp | Halozyme Therapeutics, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 75334000 | 38190000 |
| Thursday, January 1, 2015 | 135057000 | 49503000 |
| Friday, January 1, 2016 | 146691000 | 65085000 |
| Sunday, January 1, 2017 | 316613000 | 71953000 |
| Monday, January 1, 2018 | 151862000 | 92008000 |
| Tuesday, January 1, 2019 | 195992000 | 120368000 |
| Wednesday, January 1, 2020 | 267594000 | 117483000 |
| Friday, January 1, 2021 | 443310000 | 219514000 |
| Saturday, January 1, 2022 | 660116000 | 296536000 |
| Sunday, January 1, 2023 | 829253000 | 361051000 |
| Monday, January 1, 2024 | 1015324000 |
Cracking the code
In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market position. Over the past decade, Halozyme Therapeutics, Inc. and Veracyte, Inc. have shown remarkable trajectories in their annual revenues. From 2014 to 2023, Halozyme Therapeutics has seen its revenue soar by over 1,000%, starting from a modest $75 million to an impressive $829 million. This growth reflects a compound annual growth rate (CAGR) of approximately 30%, underscoring the company's strategic advancements and market penetration.
In contrast, Veracyte, Inc. has also demonstrated significant growth, albeit at a more moderate pace. Its revenue increased from $38 million in 2014 to $361 million in 2023, marking a CAGR of around 25%. This growth highlights Veracyte's expanding influence in the diagnostic space. Both companies exemplify the potential for innovation-driven growth in the biotech sector.
Amgen Inc. or Halozyme Therapeutics, Inc.: Who Leads in Yearly Revenue?
Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.: Annual Revenue Growth Compared
Comparing Revenue Performance: Zoetis Inc. or Halozyme Therapeutics, Inc.?
Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.: A Comprehensive Revenue Analysis
Who Generates More Revenue? Catalent, Inc. or Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. and ADMA Biologics, Inc.: A Comprehensive Revenue Analysis
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Revenue Insights: Halozyme Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated Performance Compared
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Revenue Showdown: Halozyme Therapeutics, Inc. vs Geron Corporation
Revenue Insights: Corcept Therapeutics Incorporated and Veracyte, Inc. Performance Compared
Annual Revenue Comparison: Veracyte, Inc. vs Bausch Health Companies Inc.